BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Odyssey Therapeutics, Inc. Common Stock
ODTX
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $930.59M
- Price / earnings
- —
- Price / book
- 2.48×
- Price / sales
- —
- EV / sales
- —
- EV / EBITDA
- -5.85×
Profitability
- Earnings per share
- -$3.00
- Return on assets
- -32.89%
- Return on equity
- -38.35%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 0×
- Current ratio
- 12.94×
- Quick ratio
- 12.94×
- Cash ratio
- 3.09×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$149.23M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 | Q2 FY2026 Jun 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Selling, general and administrative | $11.24M | $10.51M |
| Research and development | $42.12M | $36.23M |
| Total operating expenses | $53.36M | $55.47M |
| Operating income | -$53.36M | -$55.47M |
| Interest expense | -$12K | -$20K |
| Income before taxes | -$53.01M | -$52.8M |
| Income taxes | $49K | -$8K |
| Net income | -$53.06M | -$52.79M |
| Net income attributable to common shareholders | -$53.06M | -$52.79M |
| EBITDA | -$52.35M | -$54.43M |
| Basic earnings per share | -$1.10 | -$1.74 |
| Diluted earnings per share | -$1.10 | -$1.74 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.